Liquid Select for Lung Cancer Patients

Clinically actionable for managing Stage IV non-small cell lung cancer (NSCLC) patients

  • Approved molecular marker-associated therapies for NSCLC
  • 90% of the actively recruiting Phase II-IV clinical trials for Stage IV NSCLC patients1

Liquid Biopsy for Lung Cancer

Lung cancer is the leading cause of cancer mortality in the US, accounting for 1 in 4 cancer deaths2. NSCLC accounts for 83% of lung cancers2, and 55% of lung cancer patients are initially diagnosed with advanced disease3. The use of molecular markers to guide treatment considerations for management of targeted therapy for NSCLC patients is well-established in guidelines.

Clinically Actionable for Stage IV NSCLC

The Oncotype SEQ® Liquid Select panel contains the clinically actionable genes where inclusion in NCCN® guidelines are available to support clinical intervention for stage IV NSCLC tumors. Additionally, it identifies actively enrolling Phase II-IV clinical trials that your patient may be eligible for on the basis of the genomic alterations associated with their disease.

HER2 Inhibitors EGFR Inhibitors Other Kinase Inhibitors
Approved in Stage IV NSCLC Afatinib Trastuzumab Afatinib Erlotinib Gefitinib Osimeritinib Ceritinib Crizotinib Dabrafenib Trametinib Vemurafenib Cabozantinib Alectinib
ALK ♦︎ ♦︎ ♦︎
BRAF
EGFR† ♦︎ ♦︎ ♦︎ ♦︎ ♦︎
ERBB2
KRAS
MET
RET
ROS ♦︎
♦︎ Marker included in FDA text associated with drug
■ Included in Guidelines
Resistance association in Guidelines
† EGFR T790M mutation, in conjunction with a sensitizing mutation, confers resistance for EGFR tyrosine kinase inhibitors except Osimertinib. Rociletinib is under FDA review for treatment of patients with mutant EGFR non-small cell lung cancer, who have been previously treated with an EGFR-targeted therapy and have the EGFR T790M mutation

Built for Today and Tomorrow

The Oncotype SEQ Liquid Select panel includes select emerging markers that are enrollment criteria for promising Phase II-IV clinical trials for Stage IV NSCLC patients.

Select Genes Currently Being Used in Clinical Trials for Stage IV NSCLC HER2 Targeted Therapies EGFR Inhibitors Other Kinase Inhibitors
ERBB2 o
BRAF o
ROS o
RET o
MET o o
PIK3CA o o o
PTEN o

 

1. Actual clinical trial coverage will vary based on currently enrolling trials at the time the patient test report is generated
2. American Cancer Society. Cancer facts and figures 2016. www.cancer.org
3. Spiro, Gould, Colice. ACCP evidenced-based clinical practice guidelines. Chest. 2007 Sep. 132(3 Suppl):149S-160S.

Clinically actionable for managing Stage IV non-small cell lung cancer (NSCLC) patients

  • Approved molecular marker-associated therapies for NSCLC
  • 90% of the actively recruiting Phase II-IV clinical trials for Stage IV NSCLC patients1

Liquid Biopsy for Lung Cancer

Lung cancer is the leading cause of cancer mortality in the US, accounting for 1 in 4 cancer deaths2. NSCLC accounts for 83% of lung cancers2, and 55% of lung cancer patients are initially diagnosed with advanced disease3. The use of molecular markers to guide treatment considerations for management of targeted therapy for NSCLC patients is well-established in guidelines.

Clinically Actionable for Stave IV NSCLC

The Oncotype SEQ® Liquid Select panel contains the clinically actionable genes where inclusion in NCCN® guidelines are available to support clinical intervention for stage IV NSCLC tumors. Additionally, it identifies actively enrolling Phase II-IV clinical trials that your patient may be eligible for on the basis of the genomic alterations associated with their disease.

HER2 Inhibitors EGFR Inhibitors Other Kinase Inhibitors
Approved in Stage IV NSCLC Afatinib Trastuzumab Afatinib Erlotinib Gefitinib Osimeritinib Ceritinib Crizotinib Dabrafenib Trametinib Vemurafenib Cabozantinib Alectinib
ALK ♦︎ ♦︎ ♦︎
BRAF
EGFR† ♦︎ ♦︎ ♦︎ ♦︎ ♦︎
ERBB2
KRAS
MET
RET
ROS ♦︎
♦︎ Marker included in FDA text associated with drug
■ Included in Guidelines
Resistance association in Guidelines
† EGFR T790M mutation, in conjunction with a sensitizing mutation, confers resistance for EGFR tyrosine kinase inhibitors except Osimertinib. Rociletinib is under FDA review for treatment of patients with mutant EGFR non-small cell lung cancer, who have been previously treated with an EGFR-targeted therapy and have the EGFR T790M mutation

Built for Today and Tomorrow

The Oncotype SEQ Liquid Select panel includes select emerging markers that are enrollment criteria for promising Phase II-IV clinical trials for Stage IV NSCLC patients.

Select Genes Currently Being Used in Clinical Trials for Stage IV NSCLC HER2 Targeted Therapies EGFR Inhibitors Other Kinase Inhibitors
ERBB2 o
BRAF o
ROS o
RET o
MET o o
PIK3CA o o o
PTEN o

1. Actual clinical trial coverage will vary based on currently enrolling trials at the time the patient test report is generated
2. American Cancer Society. Cancer facts and figures 2016. www.cancer.org
3. Spiro, Gould, Colice. ACCP evidenced-based clinical practice guidelines. Chest. 2007 Sep. 132(3 Suppl):149S-160S.